Independent secondary dose calculation for patient-specific quality assurance: Quantitative benefit of Monte-Carlo and custom beam modeling

针对患者个体化质量保证的独立二次剂量计算:蒙特卡罗模拟和自定义束流建模的定量优势

阅读:1

Abstract

BACKGROUND: Independent secondary dose calculation (ISDC) is becoming increasingly important for patient specific quality assurance. The most widely used analytical algorithms in ISDC are becoming challenged by Monte Carlo systems, which offer a potentially higher accuracy. PURPOSE: Quantify the benefit of Monte Carlo over analytical algorithms, and of customized beam models over generic beam models, in terms of clinically relevant parameters, action level, and workload. METHODS: A set of 100 patients across 20 case classes, all planned with Acuros XB (Siemens Healthineers) was analyzed with Mobius3D (M3D) (Siemens Healthineers) and SciMoCa (Radialogica LLC), both with custom beam models (SMCcbm) and generic beam models (SMCgen). Gamma pass rate (GPR) and mean target dose difference |ΔD| action levels were determined for various rates of QA failures. RESULTS: At a workload of < 10%, the action level for M3D was GPR (3%, 3 mm) < 90% and |ΔD| > 4.5%. For SMCgen, the action level was GPR (2%, 2 mm) < 95% and |ΔD| > 1.5%. For SMCcbm, it was GPR (2%, 1 mm) < 95% and |ΔD | > 1%. The combination of both criteria reduced the workload to < 5%. SMC failures could be traced back to differences in the patient density model of Acuros XB. Some M3D failures could be traced back to the handling of tissue heterogeneities. The different performance between SMCcbm and SMCgen was due to one (of three) generic beam models. CONCLUSION: Monte Carlo allows substantially stricter acceptance criteria and is sensitive enough to capture TPS commissioning errors. Generic beam models must be validated thoroughly before being put to use in ISDC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。